{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T13:50:23Z","timestamp":1772286623621,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,12,17]],"date-time":"2018-12-17T00:00:00Z","timestamp":1545004800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1038\/s41440-018-0169-3","type":"journal-article","created":{"date-parts":[[2018,12,17]],"date-time":"2018-12-17T10:54:50Z","timestamp":1545044090000},"page":"319-328","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Renoprotective effects of tolvaptan in hypertensive heart failure rats depend on renal decongestion"],"prefix":"10.1038","volume":"42","author":[{"given":"Hiroki","family":"Chiba","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshihiro","family":"Seo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seika","family":"Sai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikiko","family":"Namekawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Ishizu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kazutaka","family":"Aonuma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,12,17]]},"reference":[{"issue":"Suppl 1","key":"169_CR1","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1007\/s10557-011-6348-y","volume":"25","author":"M Fukunami","year":"2011","unstructured":"Fukunami M, Matsuzaki M, Hori M, Izumi T. Tolvaptan Investigators. Efficacy and safety of tolvaptan in heart failure patients with sustained volume overload despite the use of conventional diuretics: a phase III open-label study. Cardiovasc Drugs Ther. 2011;25(Suppl 1):S47\u201356.","journal-title":"Cardiovasc Drugs Ther"},{"key":"169_CR2","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1093\/eurheartj\/eht386","volume":"35","author":"K Damman","year":"2014","unstructured":"Damman K, Valente MA, Voors AA, O\u2019Connor CM, van Veldhuisen DJ, Hillege HL. Renal impairment, worsening renal function, and outcome in patients with heart failure: an updated meta-analysis. Eur Heart J. 2014;35:455\u201369.","journal-title":"Eur Heart J"},{"key":"169_CR3","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1001\/jama.297.12.1332","volume":"297","author":"M Gheorghiade","year":"2007","unstructured":"Gheorghiade M, Konstam MA, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, et al. Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA. 2007;297:1332\u201343.","journal-title":"JAMA"},{"key":"169_CR4","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1016\/j.jjcc.2012.08.020","volume":"61","author":"Y Matsue","year":"2013","unstructured":"Matsue Y, Suzuki M, Seya M, Iwatsuka R, Mizukami A, Nagahori W, et al. Tolvaptan reduces the risk of worsening renal function in patients with acute decompensated heart failure in high-risk population. J Cardiol. 2013;61:169\u201374.","journal-title":"J Cardiol"},{"key":"169_CR5","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.jjcc.2015.09.020","volume":"67","author":"K Kimura","year":"2016","unstructured":"Kimura K, Momose T, Hasegawa T, Morita T, Misawa T, Motoki H, et al. Early administration of tolvaptan preserves renal function in elderly patients with acute decompensated heart failure. J Cardiol. 2016;67:399\u2013405.","journal-title":"J Cardiol"},{"key":"169_CR6","doi-asserted-by":"publisher","unstructured":"Sen J, Chun E, McGill D. Tolvaptan for heart failure in chronic kidney disease patients: a systematic review and meta-analysis. Heart Lung Circ. (epub ahead of print 13 2018; \n                    https:\/\/doi.org\/10.1016\/j.hlc.2017.12.013\n                    \n                  ).","DOI":"10.1016\/j.hlc.2017.12.013"},{"key":"169_CR7","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1016\/j.jacc.2008.08.080","volume":"53","author":"K Damman","year":"2009","unstructured":"Damman K, van Deursen VM, Navis G, Voors AA, van Veldhuisen DJ, Hillege HL. Increased central venous pressure is associated with impaired renal function and mortality in a broad spectrum of patients with cardiovascular disease. J Am Coll Cardiol. 2009;53:582\u20138.","journal-title":"J Am Coll Cardiol"},{"key":"169_CR8","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1007\/s00380-017-1063-7","volume":"33","author":"K Komuro","year":"2018","unstructured":"Komuro K, Seo Y, Yamamoto M, Sai S, Ishizu T, Shimazu K, et al. Assessment of renal perfusion impairment in a rat model of acute renal congestion using contrast-enhanced ultrasonography. Heart Vessels. 2018;33:434\u201340.","journal-title":"Heart Vessels"},{"key":"169_CR9","doi-asserted-by":"publisher","first-page":"57","DOI":"10.21037\/cdt.2017.07.05","volume":"8","author":"Y Seo","year":"2018","unstructured":"Seo Y, Nakatsukasa T, Sai S, Ishizu T, Iida N, Yamamoto M, et al. Clinical implications of organ congestion in heart failure patients as assessed by ultrasonography. Cardiovasc Diagn Ther. 2018;8:57\u201369.","journal-title":"Cardiovasc Diagn Ther"},{"key":"169_CR10","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/j.echo.2012.11.015","volume":"26","author":"R Koshizuka","year":"2013","unstructured":"Koshizuka R, Ishizu T, Kameda Y, Kawamura R, Seo Y, Aonuma K. Longitudinal strain impairment as a marker of the progression of heart failure with preserved ejection fraction in a rat model. J Am Soc Echocardiogr. 2013;26:316\u201323.","journal-title":"J Am Soc Echocardiogr"},{"key":"169_CR11","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.2214\/ajr.154.6.2110732","volume":"154","author":"JF Platt","year":"1990","unstructured":"Platt JF, Ellis JH, Rubin JM, DiPietro MA, Sedman AB. Intrarenal arterial Doppler sonogra- phy in patients with nonobstructive renal disease: correlation of resistive index with biopsy findings. Am J Roentgenol. 1990;154:1223\u20137.","journal-title":"Am J Roentgenol"},{"key":"169_CR12","doi-asserted-by":"publisher","first-page":"1920","DOI":"10.1038\/ki.1997.261","volume":"51","author":"E Ishimura","year":"1997","unstructured":"Ishimura E, Nishizawa Y, Kawagishi T, Okuno Y, Kogawa K, Fukumoto S, et al. Intrarenal hemodynamic abnormalities in diabetic nephropathy measured by duplex Doppler sonography. Kidney Int. 1997;51:1920\u20137.","journal-title":"Kidney Int"},{"key":"169_CR13","doi-asserted-by":"publisher","first-page":"1272","DOI":"10.1248\/bpb.26.1272","volume":"26","author":"R Watanabe","year":"2003","unstructured":"Watanabe R, Matsumura M, Chen CJ, Kaneda Y, Ishihara M, Fujimaki M. Gray-scale liver enhancement with Sonazoid (NC100100), a novel ultrasound contrast agent; detection of hepatic tumors in a rabbit model. Biol Pharm Bull. 2003;26:1272\u20137.","journal-title":"Biol Pharm Bull"},{"key":"169_CR14","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.lfs.2014.06.015","volume":"110","author":"T Machino","year":"2014","unstructured":"Machino T, Murakoshi N, Sato A, Xu D, Hoshi T, Kimura T, et al. Anti-hypertensive effect of radiofrequency renal denervation in spontaneously hypertensive rats. Life Sci. 2014;110:86\u201392.","journal-title":"Life Sci"},{"key":"169_CR15","first-page":"279","volume":"238","author":"JC Burnett Jr","year":"1980","unstructured":"Burnett JC Jr, Knox FG. Renal interstitial pressure and sodium excretion during renal vein constriction. Am J Physiol. 1980;238:279\u201382.","journal-title":"Am J Physiol"},{"key":"169_CR16","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1161\/CIRCHEARTFAILURE.111.965392","volume":"5","author":"H Morooka","year":"2012","unstructured":"Morooka H, Iwanaga Y, Tamaki Y, Takase T, Akahoshi Y, Nakano Y, et al. Chronic administration of oral vasopressin type 2 receptor antagonist tolvaptan exerts both myocardial and renal protective effects in rats with hypertensive heart failure. Circ Heart Fail. 2012;5:484\u201392.","journal-title":"Circ Heart Fail"},{"key":"169_CR17","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1161\/01.RES.71.5.1153","volume":"71","author":"E Farrugia","year":"1992","unstructured":"Farrugia E, Lockhart JC, Larson TS. Relation between vasa recta blood flow and renal interstitial hydrostatic pressure during pressure natriuresis. Circ Res. 1992;71:1153\u20138.","journal-title":"Circ Res"},{"key":"169_CR18","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1007\/s11897-010-0009-5","volume":"7","author":"A Ganda","year":"2010","unstructured":"Ganda A, Onat D, Demmer RT, Wan E, Vittorio TJ, Sabbah HN, et al. Venous congestion and endothelial cell activation in acute decompensated heart failure. Curr Heart Fail Rep. 2010;7:66\u201374.","journal-title":"Curr Heart Fail Rep"},{"key":"169_CR19","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1093\/eurheartj\/eht456","volume":"35","author":"PC Colombo","year":"2014","unstructured":"Colombo PC, Onat D, Harxhi A, Demmer RT, Hayashi Y, Jelic S, et al. Peripheral venous congestion causes inflammation, neurohormonal, and endothelial cell activation. Eur Heart J. 2014;35:448\u201354.","journal-title":"Eur Heart J"},{"key":"169_CR20","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/ki.1973.112","volume":"4","author":"T Kishimoto","year":"1973","unstructured":"Kishimoto T, Maekawa M, Abe Y, Yamamoto K. Intrarenal distribution of blood flow and renin release during renal venous pressure elevation. Kidney Int. 1973;4:259\u201366.","journal-title":"Kidney Int"},{"key":"169_CR21","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1097\/00005373-199912000-00002","volume":"47","author":"JM Doty","year":"1999","unstructured":"Doty JM, Saggi BH, Sugerman HJ, Blocher CR, Pin R, Fakhry I, et al. Effect of increased renal venous pressure on renal function. J Trauma. 1999;47:1000\u20133.","journal-title":"J Trauma"},{"key":"169_CR22","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/hr.2016.130","volume":"40","author":"M Imazu","year":"2017","unstructured":"Imazu M, Takahama H, Amaki M, Sugano Y, Ohara T, Hasegawa T, et al. Use of serum fibroblast growth factor 23 vs. plasma B-type natriuretic peptide levels in assessing the pathophysiology of patients with heart failure. Hypertens Res. 2017;40:181\u20138.","journal-title":"Hypertens Res"},{"key":"169_CR23","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1146\/annurev-physiol-030212-183727","volume":"75","author":"MC Hu","year":"2013","unstructured":"Hu MC, Shiizaki K, Kuro-o M, Moe OW. Fibroblast growth factor 23 and Klotho: physiology and pathophysiology of an endocrine network of mineral metabolism. Annu Rev Physiol. 2013;75:503\u201333.","journal-title":"Annu Rev Physiol"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41440-018-0169-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41440-018-0169-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41440-018-0169-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:20:03Z","timestamp":1684617603000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41440-018-0169-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,17]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["169"],"URL":"https:\/\/doi.org\/10.1038\/s41440-018-0169-3","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,17]]},"assertion":[{"value":"13 May 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2018","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"YS: research funds from Otsuka Pharmaceutical Co., Ltd. The remaining authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}